stockportfolio.pro
Centessa Pharmaceuticals plc (CNTA)
Healthcare · Biotechnology · NasdaqGS
Centessa Pharmaceuticals plc revenue & earnings — last 6 fiscal years
| Metric | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.85M | $0 | $15.00M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-5.06M | $-10.66M | $-216.21M | $-151.09M | $-235.76M | $-197.53M |
| Net margin | — | — | — | -2204.7% | — | -1316.9% |
Source: Centessa Pharmaceuticals plc SEC filings (10-K).
Explore 6 years of Centessa Pharmaceuticals plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CNTA in your portfolio →
Centessa Pharmaceuticals plc financial history by metric
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Centessa Pharmaceuticals plc — frequently asked questions
What is Centessa Pharmaceuticals plc's revenue?
Centessa Pharmaceuticals plc (CNTA) reported revenue of $15.00M for fiscal year 2025, according to its SEC filings.
Is Centessa Pharmaceuticals plc profitable?
No — CNTA reported a net loss of $-197.53M in fiscal 2025.
What is CNTA's P/E ratio?
Centessa Pharmaceuticals plc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Centessa Pharmaceuticals plc have?
As of fiscal year 2025, CNTA carried roughly $110.09M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Centessa Pharmaceuticals plc's market cap?
Centessa Pharmaceuticals plc (CNTA) has a market capitalization of about $6.14B, based on the latest data in our nightly-refreshed cache.
When does Centessa Pharmaceuticals plc's fiscal year end?
CNTA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Centessa Pharmaceuticals plc's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.